



## Immunogenicity of targeted therapies in psoriasis

Narrative review of the existing literature was conducted.

### Results/Answer:

A lack of fully comparable information on the formation of anti-drug antibodies against targeted therapies in psoriasis has been identified in the course of the guideline's development. Within the scope of this version of the guideline, a thorough systematic search of the available evidence has not been feasible and a consensus on consequent measures has not been achieved. The author group acknowledges that there is evidence of a beneficial effect of the combination of methotrexate with adalimumab from psoriasis patients and MTX with infliximab in rheumatoid arthritis or Crohn's disease patients to reduce the formation in ADA.

The guideline group encourages researches to pursue further investigations into the field of anti-drug antibodies and to generate data that allows comparison between different drugs and that can lead clinically relevant recommendations.

The authors encourage further opinion papers, narrative or preferably systematic reviews to further advance the discussion on immunogenicity.<sup>1-3</sup>

### References

1. Goss SL, Klein CE, Jin Z *et al.* Methotrexate Dose in Patients With Early Rheumatoid Arthritis Impacts Methotrexate Polyglutamate Pharmacokinetics, Adalimumab Pharmacokinetics, and Efficacy: Pharmacokinetic and Exposure-response Analysis of the CONCERTO Trial. *Clin Ther* 2018; **40**: 309-19.
2. Strik AS, van den Brink GR, Ponsioen C, Mathot R, Lowenberg M, D'Haens GR. Suppression of anti-drug antibodies to infliximab or adalimumab with the addition of an immunomodulator in patients with inflammatory bowel disease. *Aliment Pharmacol Ther* 2017; **45**: 1128-34.
3. Van der Kraaij GE, et al. EADV Congress Poster, FC02.06. In. 2019.